New Drug to Treat Chemotherapy Overdose Receives FDA Approval

The most common complication faced by cancer patients is chemotherapy overdose. The drug used in chemotherapy 5-fluorouracil (5-FU) or capecitabine is known for causing severe toxicity affecting the cardiac or central nervous system and allergic reactions in patients.

The Food and Drug Administration (FDA) has recently approved a drug called Vistogard (uridine triacetate) for treating patients suffering from chemotherapy overdose. The drug has showed positive results in its final clinical trial.

Combining Capecitabine and Temsirolimus Safe and Effective in Patients With Advanced Malignancies
Combining capecitabine and temsirolimus for treating advanced malignancies is effective and can safely be given to patients, according to a phase I study.

‘FDA approves Vistogard or uridine triacetate for treating patients suffering from chemotherapy overdose.’

Tweet it Now

Uridine triacetate was tested on 135 adult and pediatric patients in two separate trials who had either overdosed on 5-FU or experienced life-threatening adverse events within 4 days of receiving 5-FU infusion therapy. Of those patients treated for overdose, 97% were alive after 30 days. Of those treated for toxicities, 89% were alive at 30 days.

The drug developed by Wellstat Therapeutics should be taken soon after overexposure - regardless of whether symptoms are present or early onset of severe toxicities, including severe mucositis, fever, diarrhea, or rash.

Source-Medindia

Capecitabine With Concurrent Chemoradiation Effective on Gastric Cancer
Gastric cancer is a major cause of cancer deaths in the world. The outcome of large gastric tumors and those with lymph node involvement remains poor after surgical resection. The

Eribulin Treatment in Women With Breast Cancer Improved Overall Survival
Results from a phase III clinical trial comparing a newer chemotherapy agent called eribulin mesylate with capecitabine showed that eribulin demonstrated a trend toward improved overall survival.

Netupitant/Palonosetron for Prevention of Chemotherapy Induced Nausea and Vomiting
No added benefit was proven in moderately emetogenic or in highly emetogenic chemotherapeutic regimens with the drug combination of Netupitant/palonosetron.